Remove 2022 Remove Innovation Remove Pulmonary
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Latest Medical News: Partial Heart Transplant of an Infant

Wellnest

This innovative technique not only provides functional heart valves for neonates but also offers the promise of lifelong solutions, transforming the landscape of pediatric heart surgeries. The surgical team skillfully dissected the pulmonary artery ostia and coronary artery buttons, preparing for the intricate transplant.